Back to search

BEHANDLING-God og treffsikker diagnostikk, behandling og rehabilitering

Targeting Aging and improving patient outcome with Nicotinamide Riboside

Alternative title: Nikotinamid ribosid i aldersrelaterte sykdommer

Awarded: NOK 8.4 mill.

Project Number:

288579

Application Type:

Project Period:

2019 - 2024

Location:

Partner countries:

The supplement nicotinamide riboside is a vitamin B3 derivate that is safe in humans and has shown multiple beneficial effects in animal studies. In this early phase randomized study we will explore tolerability and find the right dose of this vitamin for hospitalized patients. In the study we will use new measurements for biological age to explore how they can be applied in clinical studies. These methods are extremely promising both for measuring age and for increasing our understanding of the aging process itself. However, they are new and have seldom been applied in the clinic. By using these methods in a clinical study we will not only learn about the effects of nicotinamide riboside on aging but also about the process of aging and about how these measurement methods can be used for early detection of new harmful chemicals and drugs. If these methods had been available when cigarettes were introduced we could have detected their harmful influence within a year. However, validation of the new and very promising methods has not been done in prospective and longitudinal studies which is what our study is about.

-

Confidential information omitted Human populations across the world are aging at an unprecedented rate. A great mystery is why some people age successfully, maintaining robust physical and mental functioning throughout a long life while others experience premature senescence affecting cellular, biological and functional health. Understanding the causes of these differences in patterns and rates of aging and investigate possible interventions is one of the most intriguing challenges confronting the biology of aging. Progress on these fronts have tremendous implications for public health. The use of the methylome offers a particularly powerful approach for capturing biological age. While it has long been known that changes in the epigenetic landscape drive development, only recently have we begun to map age-related epigenetic dysregulation and exploit new methodologies that allow us to capture such changes as important biomarkers of healthy aging and biological age. This approach holds the promise of being highly transformative; it can be used to quickly measure the effects of interventions aimed influencing the aging rate which is what we aim to test in the proposed project. Additionally, they can predict which individuals are at an elevated risk of particular age-related diseases and will, ultimately, help guide decisions in personalized medicine for treatments and interventions. More than decade of research has built a convincing case that that a dietary supplement, nicotinamide riboside (NR), is both safe in humans and prolongs lifespan through reducing the rate of aging in healthy old mice. In the proposed project, we will use NR in a clinical study and compare clinical relevant outcomes with the change over the study period of the epigenetic clocks. We will include patients with pre-diagnostic samples available in the large Norwegian Janus cohort and biobank and we will validate the long-term predictive power of the new biological age predictors in this cohort

Funding scheme:

BEHANDLING-God og treffsikker diagnostikk, behandling og rehabilitering